Introduction
Hepatitis B virus (HBV) infection is one of the most important chronic viral infections in the world. About 300 million people worldwide are chronic carriers of this virus. A signi®cant number of these carriers suer from either liver failure or hepatocellular carcinoma (HCC) at the late stage of the disease (Beasley et al., 1981; Liaw et al., 1988) . The genome of HBV contains four genes named S, C, P, and X genes (Tiollasis et al., 1985; Ganem and Varmus, 1987) . The HBV X gene product (HBx) is a 16 ± 18 kD protein which has been reported to be a transcriptional transactivator and can positively regulate the transcription of a wide variety of viral and cellular promoters (Rossner, 1992; Yen, 1996) . Recent studies argued that the X protein was also a novel protein kinase (Wu et al., 1990) , a potent AMP kinase (Dopheide and Azad, 1996) , and a singlestranded DNA binding protein (Qadri et al., 1996) . It was also shown to modify several cellular pathways such as Jak1-STAT signaling , Ras signaling (Klein and , NF-kappa B signaling (Lucito and Schneider, 1992) , apoptotic killing by tumor necrosis factor-alpha (TNF-a) (Su and Kim et al., 1998) , nucleotide excision repair pathway (Becker et al., 1998) , and particularly the tumor suppressor p53 mediated process (Feitelson et al., 1993; Wang et al., 1995; Greenblatt et al., 1997) . Apparently, HBx is multifunctional and is believed to regulate HBV replication through activating and regulating viral and cellular genes.
Although the molecular mechanism by which HBV causes liver cancer is not well understood, the correlation between them is well established (Szmuness, 1979; Beasley et al., 1981; Feitelson, 1992; Robinson, 1994) . Because HCC develops many years after infection, HBV appears not to be an acutely transforming virus and multiple stages may be required for HCC to develop. Lines of evidence suggest that continuously vigorous hepatocytes destruction and regeneration may be one of the major factors (Chisari et al., 1989; Dunsford et al., 1990) . However, in some patients, HCC may develop without evidence of vigorous hepatocytes regeneration suggesting that viral factor alone may be sucient (Ohaki et al., 1983) . It was shown that transgenic mice harboring the X gene may develop hepatic adenoma and subsequently hepatocellular carcinoma, although contradictory results have been obtained by other groups (Lee et al., 1990; Kim et al., 1991) .
During the course of chronic hepatitis B infection, mutations may occur throughout the genome. These mutations re¯ect the attempt of the virus to adjust itself to the host immunity. In Taiwan, most HBV carriers were infected since their childhood (Liaw, 1994) . The virus thus inhabited the host for a much longer period of time than it did in patients of the western world, presumably facilitating the development of mutant viruses. Our recent studies showing high prevalence of HBV precore-stop-codon mutant in Taiwan were consistent with this view (Chu et al., 1996; Yeh et al., 2000b) . Based on these observations, it is possible that various novel HBx mutations occur during chronic HBV infection in Taiwanese patients. In fact, in other areas, several X deletion mutants have already been identi®ed (Feitelson et al., 1995; Hsia et al., 1997) . In this study, we aimed to analyse HBx gene sequences obtained from the sera of patients with or without hepatocellular carcinoma.
Results
A mutation hot spot in HBx (serine31-to-alanine) was identified in the serum samples of Taiwanese patients with HCC Sera from seven patients with HCC and seven patients with chronic hepatitis B were subjected for HBx sequence analysis. A serine-to-alanine amino acid substitution at codon 31 was found in ®ve of seven patients with HCC but in only one of seven patients with chronic hepatitis B (Figure 1 ). Other amino acid substitutions which occurred more than once in HCC patients included phenylalanine-to-valine at codon 132 and cysteine-to-glycine or serine at codon 187. Otherwise, amino acid substitutions occurred only randomly in patients with HCC.
Distribution of HBx-A31 mutant
After the aforementioned experiment, HBx-A31 mutant was sought in 77 and 100 randomly selected HCC and chronic hepatitis B patients. PCR ampli®cation for HBx coding region was successful in 67 of 77 HCC patients and in all 100 chronic hepatitis B patients. The basic data of these patients are listed in Table 1 . Using a dual ampli®cation created restriction site method, the amino acid of codon 31 can be partly determined (Figures 2 and  3 ; also see Materials and methods). The distribution of codon 31 variants in this study is shown in Table 2 . HBx-A31 was identi®ed in 35 of 67 (52%) patients with HCC but in only 12 of 100 (12%) patients with chronic hepatitis B (P50.001). When strati®ed for age, a signi®cant dierence was still present in two of the age groups. In patients between 40 ± 49 years of age, 14 of 19 (74%) patients with HCC versus 2 of 11 (18%) patients with chronic hepatitis B have HBx-A31 mutant (P50.005). In patients between 50 ± 59 years of age, 5 of 10 (50%) patients with HCC versus 0 of 11 patients with chronic hepatitis B have HBx-A31 mutant (P50.05). Overall, 32 of 54 (59%) of patients with HCC versus 3 of 25 (12%) patients with chronic hepatitis B over 40 years-of-age have HBx-A31 mutant (P50.001). For patients with hepatocellular carcinoma, HBx-A31 was more frequently found in patients over 40 years-of-age (32/54 versus 3/13, P50.02), whereas for patients with chronic hepatitis B, no such distinction was made. Since the majority of patients with HCC also had liver cirrhosis, the hepatitis group patients were divided into patients with or without liver cirrhosis. It was found that HBx-A31 occurred in seven of 16 (44%) patients with liver cirrhosis but in only ®ve of 84 (6%) patients without cirrhosis (P50.001).
Emergence of HBx-A31 mutant from the wild type HBx sequence
To understand whether HBx-A31 was truly a mutant emerging from the wild type sequence or just a preexisting variant, we have analysed serial serum samples from two patients who had been followed at our clinic for more than 10 years before HCC developed ( Figure  4 ). Patient A was a male, 39 years of age on his ®rst visit to our clinic, and was followed for 12 years. Liver biopsies showed bridging hepatic necrosis in 1982 and active liver cirrhosis in 1984. Fluctuated serum transaminase and AFP levels indicated repeated exacerbations of hepato-necroin¯ammation which were more severe during 1981 ± 1983. HCC developed in 1993. Sequence analysis showed wild type X sequence (S31) in 1981. HBx-A31 emerged in the beginning of 1982. HBV DNA level was 993 pg/ml when wild type X sequence was detected but gradually decreased to an undetectable level after the emergence of HBx-A31. Patient B was a male, 43 years of age. Liver biopsies showed active liver cirrhosis ever since 1983.
Five peaks of serum transaminase levels indicated occasional exacerbations of hepato-necroin¯ammation during the course. HCC developed in 1995. Sequence analysis showed a variant X sequence at codon 31 (P31) in 1983. HBx-A31 emerged and a mixture of two viruses was detected in 1985. Subsequently, only HBx-A31 was detected during 1986 ± 1992. Strikingly, the mutant reversed to wild type sequence (P31) again since 1993 before the development of HCC in 1995. Similarly, HBV DNA level gradually decreased to an undetectable level after the emergence of HBx-A31.
Differential transactivation efficacy between wild type HBx and HBx-A31
HBV enhancer I-X promoter sequence and enhancer II-C promoter sequence were inserted into a plasmid Figure 1 Identi®cation of a mutation hot at codon 31 of HBx in Taiwanese patients with HCC. A reference sequence (ADW2), serotype adw2 (GenBank accession number X02763) was listed at the top row. Sera from seven patients with HCC and chronic hepatitis (CH), respectively, were analysed. Dash (7): amino acid residue the same as in ADW2. Underlined amino acid: a mixture of wild type and mutant sequences in the serum sample encoding luciferase to obtain the reporter plasmids pEN1P-Luc and pEN2P-Luc, respectively. pCMV-Xwt and pCMV-Xmt were constructed to express wild type HBx and HBx-A31 (see Materials and methods). The results were summarized in Figure 5 . Transfection eciency was monitored by comparing the relative amount of cellular X mRNA using Northern blot analysis. Cotransfection of pEN1P-Luc and pCMVXwt into HepG2 cells showed 15 ± 40-(mean=22) fold increase of luciferase activity, whereas cotransfection of pEN1P-Luc and pCMV-Xmt showed only 4 ± 10-(mean=6) fold increase (P50.001). In contrast, Cotransfection of pEN2P-Luc and pCMV-Xwt showed 1 ± 10-(mean=5) fold increase of luciferase activity, whereas cotransfection of pEN2P-Luc and pCMV-Xmt showed 2 ± 9-(mean=6) fold increase (P40.1).
HBV genome containing HBx-A31 mutation replicated less efficiently in HepG2 cells
A well established method was used to compare the relative replication eciency (Yeh et al., 2000a) . Two plasmids, pCMV-HBV and pCMV-HBV-Xmt, which encoded a greater-than-unit-length HBV genome containing respectively wild type HBx and HBx-A31 mutation, were transfected into HepG2 cells. Transfection eciency was monitored by cotransfecting a luciferase expression plasmid, pGL2-Control (Promega, Madison, WI, USA) HBV replication intermediates was detected by Southern blot analysis ( Figure 6 ). The amount of relaxed-circular HBV DNA was about 8 ± 11-fold less in HepG2 cells transfected with pCMV-HBV-Xmt.
HBx-A31 was less potent in enhancing TNF-a induced increment of CPP32/caspase 3 activities in HepG2 cells pCMV-Xwt and pCMV-Xmt, which encoded wild type HBx and HBx-A31 sequences respectively, were used to establish HepG2 stable transformants. Northern analysis was used to determine the relative expression patterns not found in this study; solid, shaded and empty squares: completely, partially and not digested by the restriction enzymes Figure 3 An example of the result of dual ampli®cation created restriction site method. Two serum samples containing G and T, respective, at the ®rst nucleotide of HBx codon 31 were used for analysis. lanes 1 ± 3, AvaI digestion; lanes 5 ± 7, MwoI digestion; lane 4, molecular weight marker, GT, a mixture of both sera; UD, undigested; D, digested levels of X mRNA. Three cell lines, HepG2-Xwt, HepG2-XmtH, and HepG2-Xmt, were selected and expanded for this experiment. The relative amount of X mRNA in these three cell lines were 1 : 100 : 5 according to Northern blot analysis. Baseline ICE/ Caspase 1 and CPP32/Caspase 3 activities in control HepG2 cells and the three stable transformants were thus measured. No signi®cant dierence was found for ICE/Caspase 1 activities in all cell lines, whereas HepG2-XmtH and HepG2-Xwt both showed a 2.0-(1.8 ± 2.5) fold decrease of baseline CPP32/Caspase 3 activities when compared with control HepG2 cells (P50.05). No dierence was found between HepG2-Xmt and control HepG2 cells. The data indicated that both wild type HBx and a high level of HBx-A31 mutant could mildly suppress Caspase 3 activities in HepG2 cells. This data was consistent with a previous report (Gottlob et al., 1998a) . Several previous reports indicated that culture cells can be sensitized by HBx to apoptotic killing by TNFa (Su et al., 1997; Kim et al., 1998) . We therefore measured both Caspase 1 and 3 activities in these four HepG2 cell lines in the presence or absence of TNF-a (Figure 7) . None of the four cell lines showed a signi®cant increase of ICE/Caspase 1 level after addition of TNF-a. However, all four cell lines showed were marked at the bottom of the diagram. The presence of HBx-A31, wild type HBx, and a mixture of the two were marked by solid, empty and shaded squares, respectively. HBV-DNA in pg/ ml were measured using a commercially available HBV-DNA quantitation test (Naxcor, Menlo Park, CA, USA). N, HBV-DNA lower than detection limit (1.8 pg/ml) Figure 5 Transactivation assay of HBx and HBx-A31. PCMVXmt, -Xwt, and -Xrvs encoded HBx-A31, wild type HBx, and a reversed X reading frame (as a control). pEN1P-Luc and pEN2P-Luc contained the HBV enhancer 1-X promoter and enhancer 2-C promoter complex, respectively, upstream of a luciferase gene. Relative luciferase activities were calculated by taking the result of pEN1P-Luc/pCMV-Xrvs (shaded bars) or pEN2p-Luc/pCMVXrvs (solid bar) cotransfection as 1.0-fold. Short lines above the bars indicated the standard deviations of three independent experiments a signi®cant increase of CPP32/Caspase 3 activities with the addition of TNF-a into the medium. HepG2-Xwt showed a larger degree of increment than did control HepG2 cells (4.3-versus 2.8-fold; P50.01), which was consistent with other previous studies. HepG2-Xmt and control HepG2 cells showed a similar level of increase in CPP32/Caspase 3 activities (2.8-and 2.9-fold of increase; P40.1), indicating that HBx-A31 at this expression level was incapable of enhancing TNF-a induced apoptosis in HepG2 cells. However, a cell line, HepG2-XmtH, expressing high levels of HBx-A31, can also enhance TNF-a induced increment of CPP32/Caspase 3 activities in HepG2 cells. The eect was similar to that of HepG2-Xwt. These results indicated that although HBx-A31 could enhance TNF-a induced increment of CPP32/Caspase 3 activities, a much higher level of expression was required.
Discussion
In this study, we have identi®ed a point mutation in the X reading frame that frequently occurred in the late stage of chronic HBV infection. A search of the sequence data bank showed that this point mutation (alanine-31) occurred in only one of 224 reported HBx isolates (0.45%). Codon 31, in a great majority of HBx sequences in the GenBank was serine, whereas in 18 of 224 (8%) isolates, it was proline. Thus, serine-31 and proline-31 were considered the two common HBx variants. In this study, however, we found high prevalence of HBx-A31 in our population (52% in HCC patients). Even in non-cirrhotic, non-HCC patients, there were still 6% of them harboring this mutation. Similarly, we found 10% of our patients harboring threonine-31, a substitution not found in the GenBank. The reason for this discrepancy is unclear. One possible explanation is that HBV infection in Taiwan occurred mostly in the early childhood (Liaw, 1994) . Therefore, HBV persisted in the host for a much longer period of time which facilitated a generation of various mutants. In patients with chronic hepatitis, the prevalence of HBx-A31 did not increase with age but was closely related to the presence of liver cirrhosis, suggesting that a long-standing in¯ammatory process rather than age itself was the cause of HBx-A31 mutation. The prevalence is similar between patients with liver cirrhosis and patients with HCC, suggesting that emergence of this mutant did not immediately lead to HCC. Instead, this mutant likely occurred during the development of liver cirrhosis.
The results of site directed mutagenesis experiments suggested that HBx-A31 was less potent in transactivating HBV viral genes, less eective in supporting HBV replication, and less eective in enhancing TNF-a induced apoptosis. Taken together, emergence of HBx-A31 has presumably resulted from the host's selection for viruses which express less viral proteins and replicate in a lower level to escape immune surveillance. The previously identi®ed X deletion mutants likely served the same purpose. Decreased eectiveness in enhancing TNF-a induced apoptosis might serve to prevent the vigorously regenerated hepatocytes from being damaged by various interleukins and likely contributed to the process of multiple-steps hepato- carcinogenesis. Our data, however, did not support the notion that HBx-A31 itself was a potent oncogenic protein. In patient B (Figure 4 ), HBx-A31 actually reverse to wild type before development of HCC. In our HCC patients younger than 40 years old, no increased prevalence of HBx-A31 was observed ( (Schuster et al., 2000) . Although the transactivation domain of HBx has been mapped to the carboxyl portion, the amino terminal was found to have regulatory function and might repress transactivation of HBx (Murakami et al., 1994) . Furthermore, it was recently found that the amino terminal (amino acid 1 ± 50) but not the transactivation domain was important for cell transformation (Gottlob et al., 1998b) . The presence of HBx-A31 mutation in Taiwanese HCC patients further argued for the importance of the HBx amino terminal domain.
In summary, we have identi®ed a prevalent HBV X protein mutant (alanine-31) in Taiwanese patients with liver cirrhosis and HCC. This mutant is less potent in transactivating HBV viral genes, less eective in supporting HBV replication, and less eective in enhancing TNF-a induced apoptosis. Development of this mutant might represent a strategy of the virus to escape immune surveillance and thus contribute to the process of multiple-step hepatocarcinogenesis.
Materials and methods

Subjects
From 1995 ± 1998, 100 and 77 patients with chronic hepatitis B and HBV related HCC respectively, were randomly selected from patients who received liver biopsy and had their sera well-stored in our serum bank. All patients were tested negative for antibody to hepatitis C virus and positive for hepatitis B virus surface antigen. PCR for HBx coding region was successful in all 100 patients with chronic hepatitis B and in 67 patients with HCC. These 167 samples were included for HBx-A31 analysis.
DNA extraction and PCR
Serum (100 ml) was mixed with 300 ml of buer (13.3 mM Tris-HCl, pH 8.0; 6.7 mM EDTA; 0.67% sodium dodecyl sulfate; 133 mg/ml proteinase K) and incubated at 708C for 3 h. Two phenol-chloroform extractions were followed by one chloroform extraction, and DNA was precipitated with ethanol. The precipitate was dissolved in 20 ml of TE buer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA). PCR was performed with 10 ml of DNA, 2 U of Super Tag (HT Biotechnology, Ltd., Cambridge, UK), 200 mM dNTP, 100 pmole of each primers, and the provided PCR reaction buer. The primers were p1300: 5'-GCTCGCAGCCGG-TCTGGAGC-3' (nucleotide 1300 ± 1319, sense) and p1925: 5'-CTTTATAAGGGACAATGTCC-3' (nucleotide 1925 ± 1906, anti-sense) . The reaction was allowed to proceed at 948C for 1 min, at 558C for 1 min, and at 728C for 2 min in each cycle. The ampli®cation was carried on for 30 cycles in a DNA Thermal Cycler (Perkin-Elmer Cetus, Emeryville, CA, USA).
Direct sequencing
The PCR product was gel-puri®ed using Gene Clean (BIO101, La Jolla, CA, USA) and sequence-analysed. Direct sequencing utilizing SequiTherm Cycle Sequencing Kits (Epicentre Technologies, Madison, WI, USA) was carried out according to the instructions provided by the manufacturer's manual. S-dATP (Amersham, Arlington Heights, IL, USA) was used for radiolabeling. The primers used for direct sequencing were the upstream and down stream primers described above. Also, three additional primers located in the central region of the X gene were used for veri®cation of the sequence. These three primers were 5'-CGGCGCTGAATCCCGCGGAC-3' (nucleotide 1438 ± 1458, sense), 5'-GCCTTCTCATCTGCCGGTCC-3' (nucleotide 1560 ± 1579, sense) and 5'-CATAAGAG-GACTCTTGGACT-3' (nucleotide 1656 ± 1675, sense).
Dual amplification created restriction site method
To determine the nucleotide sequence of HBx codon 31 for a large number of samples, we utilized the ampli®cation created restriction site method (Figures 2 and 3) . The PCR product of X coding region was subjected for another round of PCR using primer p1300 and a mismatched primer p1491: 5'-ACGAGAGAGTCCCAGCCGACCCCG-3'
(nucleotide 1491 ± 1468, anti-sense). Because of the underlined mismatched nucleotides, the resulting PCR product (192 bp) can be digested by MwoI (GCNNNNNNNGC) in the presence of a deoxyguanylate (G) instead of a deoxythymidylate (T) at the ®rst nucleotide-position of codon 31 (GCG instead of TCG). The same PCR product of X coding region was also subjected for a second round of PCR using another set of primers: p1300 and p1500: 5'-GAGAAGGGGACGA-GAGAGTCC-3' (nucleotide 1500 ± 1480, anti-sense). The resulting PCR product (201 bp) can be digested by AvaI in the presence of TCG as codon 31. When a combined GenBank (from NCBI) was searched, the third nucleotide of codon 30 was found to be deoxycytidylate (C) in all reported HBV X gene sequences. Based on this observation, the results of our double ACRS assay were interpreted as shown in Figure 2 .
Plasmid construction and site directed mutagenesis
Two plasmids, pCMV-Xwt and pCMV-Xmt, were constructed to direct the expression of wild type HBx and HBx-A31, respectively. Site directed mutagenesis was performed using a PCR-based strategy established previously (Yeh et al., 2000a) . Brie¯y, primers p1360, pA31s, pA31r, pWTs, and pWTr were synthesized. The primer sequences were: p1360: 5'-CGCGGAAATATACAAAGCTTCC-3' (nucleotide 1355 ± 1376, sense; the underlined nucleotides were engineered to create a HindIII site), pA31s: 5'-CCCTTCGCGGGGCCGCTTGG-3'
(nucleotide 1461 ± 1480, sense), pA31r: anti-sense oligonucleotides of pA31s, pWts: the same as pA31s except a T in stead of a G at the underlined position, and pWTr: anti-sense oligonucleotides of pWTs. Using pCMV-HBV as the template, two sets of PCR were performed with p1360-pA31r and pA31s-p1925 as primers. The plasmid, pCMV-HBV, was previously generated in our laboratory by inserting a wild type copy of greaterthan-unit-length HBV genome (3.37 kb; nt. 1820 ± 1990) into pRC/CMV (Invitrogen) (Yeh et al., 2000a) . The two resulting products were gel-puri®ed, mixed together, and subjected for another 10 cycles of PCR in the absence of primers. Finally, 1/50 of the mixture was used for PCR with p1360-p1925 as primers. The ®nal product was gel-puri®ed, blunt-ended, digested with HindIII, and inserted into HindIII-XbaI (bluntended) sites of pRC/CMV to obtained pCMV-Xmt. The method for the construction of pCMV-Xwt was exactly the same except that pWTs and pWTr instead of pA31s and pA31r were used. The ®nal PCR product used for pCMVXwt construction was also blunt-ended and inserted in reverse orientation into blunt-ended XbaI site of pRC/CMV to obtain pCMV-Xrvs, which served as a control plasmid. To construct the plasmids pEN1P-Luc and pEN2P-Luc, primers p1L, p1R, p2L, and p2R were synthesized. The sequences were: p1L: 5'-TGGATATCCTGCCTTAATGC-3' (nucleotide 1041 ± 1060, sense), p1R: 5'-GATGTATATTTCCGCGA-GAG-3' (nucleotide 1370 ± 1351, anti-sense), p2L: 5'-GGTCTTACATAAGAGGACTC-3' (nucleotide 1649 ± 1668, sense), and p2R: 5'-GCAAGGTGCTGGTGCGCAGA-3' (nucleotide 1820 ± 1801, anti-sense). Using pCMV-HBV as the template, two sets of PCR were performed with p1L-p1R and p2L-p2R as primers. The two resulting products were gel-puri®ed, blunt-ended and inserted into SmaI site of pGL2-Basic Vector (Promega) to obtained pEN1P-Luc and pEN2P-Luc respectively. These two resulting plasmids contained the inserted enhancer-promoter sequences followed by a luciferase reading frame. To compare the replication eciency, a plasmid, pCMV-HBV-Xmt, was contructed by replacing the 400 bp BamHI-MstI fragment (nucleotide 1400 ± 1800) in pCMV-HBV with the corresponding region isolated from pCMV-Xmt.
Cell culture and transfection
HepG2 cells were maintained in MEM containing 10% fetal bovine serum. The standard CaPO 4 precipitation method was used to transfect cells. Cells were glycerol shocked for 1 min 5 h after transfection.
Northern blot and luciferase assay RNA was extracted from cells by guanidium thiocyanate method. After phenol-chloroform extraction, nucleic acid was precipitated with isopropylalcohol, separated by electrophoresis on an agarose gel, and transfered to a nitrocellulose membrane. The sequence¯anked by primers p1360 and p1925 was used as the probe for X mRNA. The sequencē anked by the following primers was used as the probe for bactin mRNA: 5'-CACCAACTGGGACGACATGG-3' (nucleotide 301 ± 320, sense) and 5'-AGGATCTTCATGAGG-TAGTC-3' (nucleotide 651 ± 532, anti-sense). Details for probe labeling and hybridization were described elsewhere (Yeh et al., 1997 (Yeh et al., , 1998 . The density of the hybridization signal was measured by a densitometer. Luciferase assay was performed using Luciferase Assay System (Promega) according to the manufacturer's protocol. Brie¯y, the cells (60 mm dish) were rinsed twice in PBS before 250 ml of the provided Cell Culture Lysis Reagent was added. The cells were scraped o the dish and spinned in a microcentrifuge tube to remove large debris. Twenty microliter of the cell extract was mixed with 100 ml of the provided Luciferase Assay Reagent and was immediately placed in a scintillation counter. The background was measured using an extract of nontransfected cells. As indicated by the manufacturer, the luciferase concentration is linear to the square root of measured counts per minute (c.p.m) minus background c.p.m.
Isolation of HBV DNA and Southern blot analysis
Extraction of HBV DNA was performed according to a previously described protocol (Yeh et al., 1998) . Brie¯y, cells were trypsinized from the dish, rinsed with phosphatebuered saline twice and lysed with 0.5 ml of Tris-buered saline (10 mM Tris-HCl [pH 7.2], 50 mM NaCl) containing 0.5% Nonidet P-40. After a brief centrifugation in a microcentrifuge at 1500 g, the supernatant was transferred to a new tube and adjusted to 10 mM of MgCl 2 . After digested with 100 g/ml of DNase I for 30 min at 378C, EDTA was added to a ®nal concentration of 30 mM to stop the reaction. To extract HBV DNA, an equal volume of buer containing proteinase K (50 mM Tris-HCl [pH 7.2], 1 mM EDTA, 1% SDS, 0.45% NP-40, and 200 mg/ml protease K) was added and the mixture was incubated for 3 h at 558C. After two extractions with equal volumes of phenol-chloroform and one extraction with chloroform, the DNA was precipitated with acid ethanol and dissolved in TE buer (10 mM Tris [pH 8.0], 1 mM EDTA). To detect HBV DNA, the extracted samples were loaded onto a 1% agarose gel for electrophoresis before being blotted onto a nitrocellulose membrane. HBV DNA was detected by hybridization with a digoxigenin-labeled probe. The method of labeling the probe as well as the sensitivity, speci®city and eective range for quantifying HBV DNA with this probe were described elsewhere (Yeh et al., 1997 (Yeh et al., , 1998 ).
Measurement of TNF-a induced increment of caspase 1 and 3 activities
The experiment was performed according to a previously described protocol with minor modi®cations (Tai et al., 2000) . Brie¯y, approximately 5610 4 stably transfected cells were incubated in MEM, supplemented with 10% fetal bovine serum and 1 mg/ml of actinomycin D (Boehringer Mannheim). Recombinant human TNF-a (40 ng/ml; 2.86610 7 U/mg; R&D Systems) was added into the medium and the cells were incubated for 7 h at 378C before being harvested for assay. The ICE/Caspase 1 and CPP32/Caspase 3 activities were assayed using CaspACE Assay System (Promega, Madison, WI, USA) according to the manufacturer's instructions. In this study, only half of the cell extract was used for each assay.
